Amneal Pharmaceuticals (NASDAQ:AMRX) Cut to “Buy” at Wall Street Zen

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

AMRX has been the subject of a number of other research reports. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Truist Financial boosted their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Barclays upped their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. UBS Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $15.80.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $17.23 on Monday. Amneal Pharmaceuticals has a 12 month low of $7.66 and a 12 month high of $17.86. The stock has a fifty day simple moving average of $13.82 and a two-hundred day simple moving average of $13.41. The firm has a market cap of $5.50 billion, a price-to-earnings ratio of 45.34 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, equities research analysts forecast that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director directly owned 93,660 shares in the company, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AMRX. Assenagon Asset Management S.A. increased its holdings in Amneal Pharmaceuticals by 75.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after acquiring an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC bought a new position in shares of Amneal Pharmaceuticals in the third quarter worth approximately $13,833,000. Morgan Stanley increased its stake in shares of Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares in the last quarter. Finally, Penn Capital Management Company LLC bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $12,655,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.